| Back- |
 | |  | |  | |  | |  | |  | |  | |  |
OzStar Therapeutics Pty Ltd © 2018 Privacy Policy info@ozstartherapeutics.com |
News
2018
Phase 2a Clinical Trial Approved in India (6th April 2018)
Patient recruitment is anticipated by 15th June 2018.
CEO Invited to Speak at The Microbiome R&D and Business
Collaboration Congress: Asia (6th March 2018)
Presented latest insight into our technology at the conference.
Our patent granted in Russia (25th January 2018)
Russian Patent Office has granted our second patent.
2017
Our patent granted in China (17th December 2017)
China Patent Office has granted our second patent.
Our patent granted in Canada (30th October 2017)
Canadian Patent Office has granted our first patent.
CEO Invited as a keynote speaker at The International Diabetes
and Degenerative Diseases Conference (18th September 2017)
Discussed the latest insight into our technology.
Our patent granted in USA (17th November 2017)
US Patent Office has granted our second patent.
Certificate of Special Congressional Recognition (01 February 2017)
52nd District, California
2016
Most Innovative New Product Finalist (6th October 2016)
OzStar Therapeutics and GlyConMedics has been elected as a finalist at the
2016 Most Innovative New Product Award, administered by CONNECT in San Diego, CA.
Microbiome R&D and Business Collaboration Forum (3-4 October 2016)
OzStar CEO attended the 4th Microbiome Congress held in San Diego, CA.
Diabetes Innovation Challenge Semi-Finalist (16th August 2016)
OzStar Therapeutics has been elected as a semi-finalist at the Diabetes Innovation Challenge contest, administered by T1D Exchange and M2D2 Clinical, held
at University of Massachusetts, Boston.
China granted OzStar first Patent (16th March 2016)
Chinese Patent Office has granted OzStar Therapeutics first patent.
USA granted OzStar first Patent (26th January 2016)
United States Patent and Trademark Office has granted OzStar Therapeutics first patent.
Australia USA Business Week (16th - 26th Feb February 2016)
OzStar CEO attended the inaugural Australia United State Business Week (AUSBW) that was held in six key cities across the United States – Boston, Chicago,
Houston, Los Angeles, New York and San Francisco.
2015
23rd World Diabetes Congress (30th November - 04 December 2015)
OzStar CEO attended world diabetes congress organized by the International Diabetes Federation held at Vancouver, British Columbia, Canada
Clinical Trial Conduct (14th October 2015)
OzStar's phase 2 clinical trial has been approved by a Human Research Ethics Committee in India.
2014
Clinical Trial Conduct (4th December 2014)
OzStar's phase 2 clinical trial has been approved by a Human Research Ethics Committee in Australia.
Australia granted OzStar first Patent (27th October 2014)
IP Australia has granted OzStar Therapeutics first patent.
Advisory and scientific Board (1st September 2014)
Professor Lesley Campbell has joined OzStar’s scientific advisory board.
Advisory and scientific Board (28h August 2014)
Dr Ivan Rajkovic has joined OzStar’s scientific advisory board.
Phase 2 Clinical Trials (16th June 2014)
OzStar Therapeutics has initiated its proof of concept clinical trial.
Angel Investment (4th June 2014)
OzStar Therapeutics has secured its first round of Angel Investments.
OzStar's second Patent has entered the national phase (23th May 2014)
Second PCT patent (PCT/AU2012/001442) entitled “Improved Synergistic Anti-Diabetic Compositions”, entered national phase in major countries.
Advisory and scientific Board (20th May 2014)
Professor Anthony Barnett has joined OzStar’s scientific advisory board.
Commercialisation Australia Grant (12th May 2014)
OzStar Therapeutics has received its proof-of-concept grant from The Australian Government to further develop its product and services.
Australia Week In China (4th Apr 2014)
OzStar CEO attends Australia Week in China 2014 Conference organized by AusTrade to initiate dialogues with Chinese entities.
2013
Commercial Agreements (24th Dec 2013)
OzStar has signed terms sheets with two world-leading entities to further develop its anti-diabetes tablet.
Advisory and scientific Board (7th Dec 2013)
Professor C. Ronald Kahn Chief Academic Officer of Joslin Diabetes Center, Boston has joined OzStar’s scientific advisory board.
OZ101 tablets (7th December 2013)
OzStar Therapeutics has manufactured its first GMP tablet OZ101 to conduct its proof-of-concept clinical trial.
Acceptance of First Patent (17th June 2013)
First patent entitled “Anti-Diabetic Compositions and Methods” granted in Australia.
First patent entitled “Anti-Diabetic Compositions and Methods”, entered national phase in major countries.
2012
Advisory and scientific Board (13th Sep 2012)
Professor Sanjoy Paul has joined OzStar’s scientific advisory board.
Board of Directors (19th July 2012)
Professor Tim Hirst has been appointed as company chairman of the board.
2011
IPRP (WIPO) report on OzStar first patent (6th Dec 2011)
International preliminary report on OzStar’s first PCT patent application (PCT/AU2011/000622) entitled “Anti-Diabetic Compositions and Methods” has been
received “No Prior Art” and “All claims are novel and inventive” notice on patentability from World International Patent Organization Authority.
ISR (IP Australia) written opinion on first patent (24th Aug 2011)
Examination of OzStar’s first PCT patent application (PCT/AU2011/000622) entitled “Anti-Diabetic Compositions and Methods” has been received “No Prior Art”
and “All claims are novel and inventive” notices on patentability from IP Australia International Search Report Authority.
Commercialisation Australia Grant (11th May 2011)
The Australian government has recognized the potential of OzStar’s innovation by awarding the Company with a skills and knowledge grant to further develop
its product and services.
OzStar Therapeutic Trade Mark Registration (17th Jan 2011)
OzStar Therapeutics trade mark registration No 1363963 was successful and accepted by IP Australia.
2010
OzStar Therapeutic Directors (28th Apr 2010)
Dr Nick N Gorgani and Ms. Mahnoosh Afkham have been appointed as the company Managing Director and Secretary, respectively.
OzStar Therapeutic Founded (28th Apr 2010)
OzStar Therapeutics has been founded by Dr Nick N Gorgani and Ms. Mahnoosh Afkham.
Phase 2a Clinical Trial Approved in India (6th April 2018)
Patient recruitment is anticipated by 15th June 2018.
CEO Invited to Speak at The Microbiome R&D and Business
Collaboration Congress: Asia (6th March 2018)
Presented latest insight into our technology at the conference.
Our patent granted in Russia (25th January 2018)
Russian Patent Office has granted our second patent.
2017
Our patent granted in China (17th December 2017)
China Patent Office has granted our second patent.
Our patent granted in Canada (30th October 2017)
Canadian Patent Office has granted our first patent.
CEO Invited as a keynote speaker at The International Diabetes
and Degenerative Diseases Conference (18th September 2017)
Discussed the latest insight into our technology.
Our patent granted in USA (17th November 2017)
US Patent Office has granted our second patent.
Certificate of Special Congressional Recognition (01 February 2017)
52nd District, California
2016
Most Innovative New Product Finalist (6th October 2016)
OzStar Therapeutics and GlyConMedics has been elected as a finalist at the
2016 Most Innovative New Product Award, administered by CONNECT in San Diego, CA.
Microbiome R&D and Business Collaboration Forum (3-4 October 2016)
OzStar CEO attended the 4th Microbiome Congress held in San Diego, CA.
Diabetes Innovation Challenge Semi-Finalist (16th August 2016)
OzStar Therapeutics has been elected as a semi-finalist at the Diabetes Innovation Challenge contest, administered by T1D Exchange and M2D2 Clinical, held
at University of Massachusetts, Boston.
China granted OzStar first Patent (16th March 2016)
Chinese Patent Office has granted OzStar Therapeutics first patent.
USA granted OzStar first Patent (26th January 2016)
United States Patent and Trademark Office has granted OzStar Therapeutics first patent.
Australia USA Business Week (16th - 26th Feb February 2016)
OzStar CEO attended the inaugural Australia United State Business Week (AUSBW) that was held in six key cities across the United States – Boston, Chicago,
Houston, Los Angeles, New York and San Francisco.
2015
23rd World Diabetes Congress (30th November - 04 December 2015)
OzStar CEO attended world diabetes congress organized by the International Diabetes Federation held at Vancouver, British Columbia, Canada
Clinical Trial Conduct (14th October 2015)
OzStar's phase 2 clinical trial has been approved by a Human Research Ethics Committee in India.
2014
Clinical Trial Conduct (4th December 2014)
OzStar's phase 2 clinical trial has been approved by a Human Research Ethics Committee in Australia.
Australia granted OzStar first Patent (27th October 2014)
IP Australia has granted OzStar Therapeutics first patent.
Advisory and scientific Board (1st September 2014)
Professor Lesley Campbell has joined OzStar’s scientific advisory board.
Advisory and scientific Board (28h August 2014)
Dr Ivan Rajkovic has joined OzStar’s scientific advisory board.
Phase 2 Clinical Trials (16th June 2014)
OzStar Therapeutics has initiated its proof of concept clinical trial.
Angel Investment (4th June 2014)
OzStar Therapeutics has secured its first round of Angel Investments.
OzStar's second Patent has entered the national phase (23th May 2014)
Second PCT patent (PCT/AU2012/001442) entitled “Improved Synergistic Anti-Diabetic Compositions”, entered national phase in major countries.
Advisory and scientific Board (20th May 2014)
Professor Anthony Barnett has joined OzStar’s scientific advisory board.
Commercialisation Australia Grant (12th May 2014)
OzStar Therapeutics has received its proof-of-concept grant from The Australian Government to further develop its product and services.
Australia Week In China (4th Apr 2014)
OzStar CEO attends Australia Week in China 2014 Conference organized by AusTrade to initiate dialogues with Chinese entities.
2013
Commercial Agreements (24th Dec 2013)
OzStar has signed terms sheets with two world-leading entities to further develop its anti-diabetes tablet.
Advisory and scientific Board (7th Dec 2013)
Professor C. Ronald Kahn Chief Academic Officer of Joslin Diabetes Center, Boston has joined OzStar’s scientific advisory board.
OZ101 tablets (7th December 2013)
OzStar Therapeutics has manufactured its first GMP tablet OZ101 to conduct its proof-of-concept clinical trial.
Acceptance of First Patent (17th June 2013)
First patent entitled “Anti-Diabetic Compositions and Methods” granted in Australia.
First patent entitled “Anti-Diabetic Compositions and Methods”, entered national phase in major countries.
2012
Advisory and scientific Board (13th Sep 2012)
Professor Sanjoy Paul has joined OzStar’s scientific advisory board.
Board of Directors (19th July 2012)
Professor Tim Hirst has been appointed as company chairman of the board.
2011
IPRP (WIPO) report on OzStar first patent (6th Dec 2011)
International preliminary report on OzStar’s first PCT patent application (PCT/AU2011/000622) entitled “Anti-Diabetic Compositions and Methods” has been
received “No Prior Art” and “All claims are novel and inventive” notice on patentability from World International Patent Organization Authority.
ISR (IP Australia) written opinion on first patent (24th Aug 2011)
Examination of OzStar’s first PCT patent application (PCT/AU2011/000622) entitled “Anti-Diabetic Compositions and Methods” has been received “No Prior Art”
and “All claims are novel and inventive” notices on patentability from IP Australia International Search Report Authority.
Commercialisation Australia Grant (11th May 2011)
The Australian government has recognized the potential of OzStar’s innovation by awarding the Company with a skills and knowledge grant to further develop
its product and services.
OzStar Therapeutic Trade Mark Registration (17th Jan 2011)
OzStar Therapeutics trade mark registration No 1363963 was successful and accepted by IP Australia.
2010
OzStar Therapeutic Directors (28th Apr 2010)
Dr Nick N Gorgani and Ms. Mahnoosh Afkham have been appointed as the company Managing Director and Secretary, respectively.
OzStar Therapeutic Founded (28th Apr 2010)
OzStar Therapeutics has been founded by Dr Nick N Gorgani and Ms. Mahnoosh Afkham.
